Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.
- DOI
- 10.1136/rmdopen-2023-003977
- Published
- 2024 Mar 26
- Container
- RMD open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/rmdopen-2023-003977,
title = {Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.},
author = {Coates LC and Gossec L and Zimmermann M and Shawi M and Rampakakis E and Shiff NJ and Kollmeier AP and Xu XL and Nash P and Mease PJ and Helliwell PS},
year = {2024},
journal = {RMD open},
doi = {10.1136/rmdopen-2023-003977},
url = {https://doi.org/10.1136/rmdopen-2023-003977}
}RIS
TY - JOUR TI - Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study. AU - Coates LC AU - Gossec L AU - Zimmermann M AU - Shawi M AU - Rampakakis E AU - Shiff NJ AU - Kollmeier AP AU - Xu XL AU - Nash P AU - Mease PJ AU - Helliwell PS PY - 2024 JO - RMD open DO - 10.1136/rmdopen-2023-003977 UR - https://doi.org/10.1136/rmdopen-2023-003977 ER -
APA
LC, C., L, G., M, Z., M, S., E, R., NJ, S., AP, K., XL, X., P, N., PJ, M., & PS, H. (2024). Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.. RMD open. https://doi.org/10.1136/rmdopen-2023-003977
Source records
- pubmed · retrieved 2026-09-25T08:43:44.270Z